Search - tctmd.com

Displaying 21 - 37 of 37

Sort: Relevancy | Date

News Conference News EAS 2018

Biology in the Back Seat: EAS 2018 Opens With Calls for a Big-Picture Approach to CVD Prevention

Yael L. Maxwell

May 07, 2018

News Daily News

Alirocumab Price Slashed in Deal With Express Scripts

Michael O'Riordan

May 03, 2018

News Daily News

LPA Variants Linked With CHD Events in Statin-Treated Patients

Michael O'Riordan

May 03, 2018

News Daily News

The Higher the LDL, the Bigger the Mortality Benefit of Intensive Therapy: Meta-analysis

Michael O'Riordan

April 20, 2018

News Daily News

Silent MI Often Precedes Acute MI, Portends Worse Patient Outcomes

Shelley Wood

April 18, 2018

News Daily News

Pills or Even Tea More Palatable Than Exercise for the Treatment of Hypertension, US Adults Say

Michael O'Riordan

April 09, 2018

News Conference News ACC 2018

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Michael O'Riordan

March 20, 2018

News Conference News ACC 2018

ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins

Shelley Wood

March 10, 2018

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Shelley Wood

March 05, 2018

News Daily News

Nonstatin Use and Expenditures Are Up Despite the Dearth of Evidence Supporting Efficacy

Yael L. Maxwell

January 29, 2018

News Daily News

Maze of Prior Authorization for PCSK9 Inhibitors Poses Challenge to Prescribers

Yael L. Maxwell

January 24, 2018

News Daily News

Role of Lp(a) Still to Be Determined, but NHLBI Sees a Path Forward

Michael O'Riordan

January 09, 2018

News Daily News

The Biggest News of 2017: TCTMD’s Top 10

Shelley Wood

January 01, 2018

Presentation Controversies and Advances 2017

PCSK9 Inhibitors - Are They Worth The Money?

Presenter: Michael J. Blaha

November 16, 2017

Video

» On Record

On Record: The ODYSSEY Continues with PCSK9 Inhibitors

July 3, 2018

CME

Advertisement

Biology in the Back Seat: EAS 2018 Opens With Calls for a Big-Picture Approach to CVD Prevention

Alirocumab Price Slashed in Deal With Express Scripts

LPA Variants Linked With CHD Events in Statin-Treated Patients

The Higher the LDL, the Bigger the Mortality Benefit of Intensive Therapy: Meta-analysis

Silent MI Often Precedes Acute MI, Portends Worse Patient Outcomes

Pills or Even Tea More Palatable Than Exercise for the Treatment of Hypertension, US Adults Say

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Nonstatin Use and Expenditures Are Up Despite the Dearth of Evidence Supporting Efficacy

Maze of Prior Authorization for PCSK9 Inhibitors Poses Challenge to Prescribers

Role of Lp(a) Still to Be Determined, but NHLBI Sees a Path Forward

The Biggest News of 2017: TCTMD’s Top 10

PCSK9 Inhibitors - Are They Worth The Money?

On Record: The ODYSSEY Continues with PCSK9 Inhibitors

Severe/Resistant Hypercholesterolemia: New Agents Redefining Clinical Practice

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content